CY1112575T1 - Βελτιωμενα αδρανοποιημενα εμβολια fcv - Google Patents

Βελτιωμενα αδρανοποιημενα εμβολια fcv

Info

Publication number
CY1112575T1
CY1112575T1 CY20111101260T CY111101260T CY1112575T1 CY 1112575 T1 CY1112575 T1 CY 1112575T1 CY 20111101260 T CY20111101260 T CY 20111101260T CY 111101260 T CY111101260 T CY 111101260T CY 1112575 T1 CY1112575 T1 CY 1112575T1
Authority
CY
Cyprus
Prior art keywords
fcv
improved
vaccines
inactivated
immunogenic compositions
Prior art date
Application number
CY20111101260T
Other languages
English (en)
Inventor
Hervé Poulet
Denis Barral
Original Assignee
Merial Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Limited filed Critical Merial Limited
Publication of CY1112575T1 publication Critical patent/CY1112575T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16061—Methods of inactivation or attenuation
    • C12N2770/16063—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με βελτιωμένα αδρανοποιημένα εμβόλια καλυκοϊού των αιλουροειδών (FCV). Η εφεύρεση παρέχει επίσης μια διεργασία για την παρασκευή σταθεροποιημένου αδρανοποιημένου FCV, και την χρήση τέτοιου σταθεροποιημένου αδρανοποιημένου FCV, στην παραγωγή ανοσογόνων συνθέσεων του FCV. Η εφεύρεση παρέχει περαιτέρω μεθόδους επαγωγής μιας ανοσιακής απόκρισης σε ένα ζώο της οικογένειας των αιλουροειδών (Falidae), κατά προτίμηση σε μια γάτα, χρησιμοποιώντας τις ανοσογόνες συνθέσεις σύμφωνα με την εφεύρεση.
CY20111101260T 2004-01-21 2011-12-20 Βελτιωμενα αδρανοποιημενα εμβολια fcv CY1112575T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53784904P 2004-01-21 2004-01-21
EP05705920A EP1734992B1 (en) 2004-01-21 2005-01-19 Improved inactivated fcv vaccines

Publications (1)

Publication Number Publication Date
CY1112575T1 true CY1112575T1 (el) 2016-02-10

Family

ID=34825947

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111101260T CY1112575T1 (el) 2004-01-21 2011-12-20 Βελτιωμενα αδρανοποιημενα εμβολια fcv

Country Status (13)

Country Link
EP (1) EP1734992B1 (el)
JP (1) JP4873632B2 (el)
CN (1) CN1933852A (el)
AT (1) ATE526034T1 (el)
CA (1) CA2553805C (el)
CY (1) CY1112575T1 (el)
DK (1) DK1734992T3 (el)
ES (1) ES2374549T3 (el)
HK (1) HK1095035A1 (el)
PL (1) PL1734992T3 (el)
PT (1) PT1734992E (el)
SI (1) SI1734992T1 (el)
WO (1) WO2005072214A2 (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7850978B2 (en) * 1999-07-16 2010-12-14 Merial Limited Vaccine against feline calicivirus
CN101461941B (zh) * 2007-12-20 2012-07-04 施怀哲维克有限公司 疫苗及其制备方法
CN103773739B (zh) * 2013-03-01 2016-06-15 上海启盛生物科技有限公司 一种猫泛白细胞减少症病毒减毒疫苗株及其应用
JP6395855B2 (ja) 2014-04-03 2018-09-26 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド ブタ流行性下痢ウイルスワクチン
CN114591405A (zh) * 2015-12-23 2022-06-07 英特维特国际股份有限公司 猫杯状病毒疫苗
RO132299A3 (ro) * 2017-06-06 2018-12-28 Fântână Raul Sorin Compoziţie şi metodă de preparare şi evaluare a unui imunogen complex numit i-spga, destinat producerii de proteine imunologic active ()
CN112877297A (zh) * 2021-03-27 2021-06-01 哈尔滨元亨生物药业有限公司 一种利用生物反应器制备猫瘟热病毒单克隆抗体的方法
CN114107170B (zh) * 2021-11-12 2023-08-29 广东省华晟生物技术有限公司 猫肾悬浮细胞系及其构建方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
US6355246B1 (en) * 1999-06-10 2002-03-12 Board Of Trustees Of Michigan State University Feline calicivirus isolated from cat urine and vaccines thereof
US6534066B1 (en) * 1999-07-16 2003-03-18 Merial Inactivated vaccine against feline calicivirosis
FR2796282B1 (fr) * 1999-07-16 2001-10-26 Merial Sas Vaccin inactive contre la calicivirose feline
US6673349B2 (en) * 1999-12-20 2004-01-06 Simon Johannes Barteling Method of inactivating microorganisms

Also Published As

Publication number Publication date
EP1734992A2 (en) 2006-12-27
CN1933852A (zh) 2007-03-21
PT1734992E (pt) 2011-12-21
WO2005072214A3 (en) 2006-09-28
SI1734992T1 (sl) 2012-01-31
JP2007522127A (ja) 2007-08-09
EP1734992A4 (en) 2009-01-21
EP1734992B1 (en) 2011-09-28
CA2553805C (en) 2013-05-21
CA2553805A1 (en) 2005-08-11
PL1734992T3 (pl) 2012-02-29
JP4873632B2 (ja) 2012-02-08
ATE526034T1 (de) 2011-10-15
HK1095035A1 (en) 2007-04-20
WO2005072214A2 (en) 2005-08-11
DK1734992T3 (da) 2011-12-05
ES2374549T3 (es) 2012-02-17

Similar Documents

Publication Publication Date Title
CY1112575T1 (el) Βελτιωμενα αδρανοποιημενα εμβολια fcv
MY149604A (en) C.perfringens alpha toxoid vaccine
TW200806316A (en) Yeast-based vaccine for inducing an immune response
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
BRPI0607551A2 (pt) vacinas de combinação de helicobacter e circovìrus porcino e métodos de uso
WO2007024941A3 (en) Polyvalent vaccine
ATE397942T1 (de) Adjuvanszusammensetzungen zur erhöhung der immunantwort bezüglich polynukleotid-basierenden impfstoffen
TN2009000557A1 (en) Influenza virus-like particles (vlps) comprising hemagglutinin produced within a plant
MX2022009167A (es) Formulaciones para vacuna contra coronavirus.
MY161965A (en) New influenza virus immunizing epitope
MX2009006178A (es) Vacuna contra salmonela.
WO2007024947A3 (en) Canine influenza vaccines
WO2006063053A3 (en) Methods of producing influenza vaccine compositions
GB2386072A (en) Novel vaccine
CA2763359C (en) New human rotavirus strains and vaccines
WO2008148057A3 (en) Cationic lipids compositions and methods for enhancing immune responses to vaccines
DK1471936T3 (da) HIV-Vaccine og fremgangsmåde til anvendelse
AR047581A1 (es) Vacunas de calicivirus felino
DE60136928D1 (de) Verwendung von pflanzen-öl-körper in impfstoffverabreichungsysteme
DE60336588D1 (de) Verbesserte anthraximpfstoffe und abgabeverfahren
ATE495758T1 (de) Virulentes systemisches felines calicivirus
DK1742656T3 (da) Hidtil ukendt jordnøddeskindekstrakt som adjuvansvaccine
AU2003294192A8 (en) Inclusion bodies as antigens for the oral vaccination of animals
ATE424844T1 (de) Kombinationsvakzine für geflügel
RU2004130267A (ru) Способ вакцинации детей против краснухи на крайнем севере